FDA approval · Drugs@FDA
TRUVADAemtricitabine, tenofovir disoproxil fumarate
NDA021752 ·
FDA approved the original new drug application for TRUVADA on August 2, 2004, sponsored by GILEAD. FDA has approved 5 efficacy supplements on the application since, the most recent on May 15, 2018.
- Application
- NDA021752
- Sponsor
- GILEAD
- Original approval
- Review
- priority review
- Submission class
- Type 4 - New Combination
- Active ingredient
- emtricitabine, tenofovir disoproxil fumarate
Browse every approval whose brand starts with T, or the complete response letters FDA has published — the applications it did not approve.
Products under this application
| Ingredient and strength | Form | Route | Marketing status |
|---|---|---|---|
| emtricitabine 167MG; tenofovir disoproxil fumarate 250MG | TABLET | ORAL | Prescription |
| emtricitabine 100MG; tenofovir disoproxil fumarate 150MG | TABLET | ORAL | Prescription |
| emtricitabine 133MG; tenofovir disoproxil fumarate 200MG | TABLET | ORAL | Prescription |
| emtricitabine 200MG; tenofovir disoproxil fumarate 300MG | TABLET | ORAL | Prescription |
Approved efficacy supplements
An efficacy supplement is how a sponsor asks FDA to approve a change that needs clinical evidence — most often a new indication. FDA’s record gives each one a submission number, a date and a review priority. It does not say what any supplement approved, so neither does this page. The approval letter and label for each are on accessdata.fda.gov under the application number.
| Approved | Supplement | Review |
|---|---|---|
| S-5 | standard | |
| S-16 | — | |
| S-30 | priority | |
| S-47 | standard | |
| S-55 | priority |
FDA records other approved supplements on this application, by the class code it assigns them: Labeling 14 · Manufacturing (CMC) 9 · REMS 4. Those are changes to the label or to how the drug is made rather than new clinical evidence, so they are counted here and not listed.
Source: FDA’s Drugs@FDA application file, via openFDA (export 2026-09-03). Every field on this page comes from that record.
An approval date is the start of the question, not the end
What a drug is worth to the company that owns it depends on what else is in the pipeline, how much cash is behind it and who else is running the same trial. FuzeBio reads a biotech end to end on demand — pipeline in plain English, trial design and endpoints, competitors, the cash position, and a valuation with its assumptions on the page. Moderna’s report is open in full, no account.
Open the Moderna reportA complete sample report — nothing held back, no sign-up.